Get the Stockscreener App
3.36
4.67%
0.15
Omeros Corporation stock is traded at $3.36, with a volume of 160.74K.
It is up +4.67% in the last 24 hours and up +4.51% over the past month.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
See More
Previous Close:
$3.21
Open:
$3.19
24h Volume:
160.74K
Relative Volume:
0.17
Market Cap:
$227.34M
Revenue:
-
Net Income/Loss:
$-117.81M
P/E Ratio:
-1.7872
EPS:
-1.88
Net Cash Flow:
$74.30M
1W Performance:
-7.18%
1M Performance:
+4.51%
6M Performance:
-54.96%
1Y Performance:
-17.85%
1-Day Range:
$3.15
$3.38
1-Week Range:
$3.15
$3.75
52-Week Range:
$2.97
$13.60
Omeros Corporation Stock (OMER) Company Profile
Name
Omeros Corporation
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corporation
|
3.36 | 227.34M | 0 | -117.81M | 74.30M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
448.69 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
516.92 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.55 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.29 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.78 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Omeros Corporation Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corporation Stock (OMER) Latest News
Ratios Revealed: Decoding Omeros Corporation (OMER)’s Financial Health - DWinneX
Omeros Co. (NASDAQ:OMER) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
What is HC Wainwright’s Forecast for Omeros FY2025 Earnings? - Defense World
HC Wainwright Predicts Omeros’ Q2 Earnings (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Now Covered by Analysts at HC Wainwright - Defense World
Cantor Fitzgerald Comments on Omeros FY2026 Earnings - Defense World
Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision - Benzinga
Trend Tracker for (OMER) - news.stocktradersdaily.com
Omeros (OMER) Receives Buy Rating from HC Wainwright & Co. | OME - GuruFocus
Omeros (OMER) Receives Buy Rating from HC Wainwright & Co. | OMER Stock News - GuruFocus
HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target - marketscreener.com
Omeros (OMER) Set for Growth with Potential Narsoplimab Approval - GuruFocus
Omeros (OMER) Set for Growth with Potential Narsoplimab Approval | OMER Stock News - GuruFocus
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program - mx.advfn.com
Omeros (NASDAQ:OMER) Stock Rating Lowered by Wall Street Zen - Defense World
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 - mx.advfn.com
OMEROmeros Corporation Reports First Quarter 2025 Financial Results - mx.advfn.com
Squarepoint Ops LLC Has $316,000 Stake in Omeros Co. (NASDAQ:OMER) - Defense World
Millennium Management LLC Buys 27,088 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Two Sigma Advisers LP Decreases Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Corporation to Host Earnings Call - ACCESS Newswire
Nuveen Asset Management LLC Reduces Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Co. (NASDAQ:OMER) Shares Bought by Two Sigma Investments LP - Defense World
Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER) - Yahoo Finance
BNP Paribas Financial Markets Has $74,000 Stock Position in Omeros Co. (NASDAQ:OMER) - Defense World
ProShare Advisors LLC Has $183,000 Position in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros Corporation to acquire $80.5 million of its convertible senior notes due 2026 - MSN
Deutsche Bank AG Has $396,000 Stock Holdings in Omeros Co. (NASDAQ:OMER) - Defense World
Omeros' Note Swap Causes Share Price Tumble - Finimize
Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster (OMER) - Seeking Alpha
Equities Analysts Issue Forecasts for Omeros FY2025 Earnings - Defense World
Omeros Co. (NASDAQ:OMER) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
Omeros (NASDAQ:OMER) Rating Increased to Hold at StockNews.com - Defense World
Omeros signals debt reduction of over $100M and prioritizes narsoplimab launch following FDA BLA acceptance - MSN
Omeros (NASDAQ:OMER) Earns Hold Rating from Needham & Company LLC - Defense World
Omeros Corporation (NASDAQ:OMER) Q1 2025 Earnings Call Transcript - Insider Monkey
Omeros Co. (NASDAQ:OMER) Shares Purchased by Comerica Bank - Defense World
Omeros Corp. Earnings Call: Cautious Optimism Amid Challenges - TipRanks
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic D - GuruFocus
Needham Reiterates Hold Rating on Omeros (OMER) | OMER Stock New - GuruFocus
Earnings call transcript: Omeros Q1 2025 sees stock rise post-earnings By Investing.com - Investing.com Nigeria
Omeros: Q1 Earnings Snapshot - CT Insider
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... - Yahoo Finance
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab Launch Plans - GuruFocus
Omeros (OMER) Achieves Milestone with FDA Acceptance of Narsopli - GuruFocus
Omeros Corporation Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Omeros Q1 2025 sees stock rise post-earnings - Investing.com
Omeros (OMER) Streamlines Debt, Preps for Narsoplimab Launch - GuruFocus
Transcript : Omeros Corporation, Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Omeros Corp Q1 2025 Earnings: EPS of -$0.58 Misses Estimates, Re - GuruFocus
Omeros reports Q1 EPS (58c), consensus (60c) - TipRanks
Omeros Corporation Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):